CH258174A - Process for the preparation of a new oxyhydrophenanthrene derivative. - Google Patents

Process for the preparation of a new oxyhydrophenanthrene derivative.

Info

Publication number
CH258174A
CH258174A CH258174DA CH258174A CH 258174 A CH258174 A CH 258174A CH 258174D A CH258174D A CH 258174DA CH 258174 A CH258174 A CH 258174A
Authority
CH
Switzerland
Prior art keywords
ethyl
methoxy
propyl
carboxylic acid
phenanthrene
Prior art date
Application number
Other languages
German (de)
Inventor
Aktiengesellschaft Ciba
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of CH258174A publication Critical patent/CH258174A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/34Unsaturated compounds containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

  

  Verfahren zur Herstellung eines neuen     Oxyhydrophenanthren-Derivates.       Es wurde gefunden, dass man zu einem  neuen     Oxyhydrophenanthren-Derivat    gelan  gen kann, wenn man ein     1-Äthyl-2-n-propyl-7-          me@thoxy-1,2,3,4-tetrahydro-phenanthren,    das  in     2-Stellung    einen durch Hydrolyse in die,  freie     Ca.rboxyl,grupp    e     überführbaren        Substi-          tuenten,    z.

   B. eine     veresterte        Carboxylgruppe,     enthält,     zwecks    Bildung     einer        freien        Carb-          oxylgruppe    mit     hydnolysierenden        Mitteln    be  handelt.  



  Das noch nicht     bekannte    Endprodukt des  Verfahrens, die 1-Äthyl-2-n-propyl-7-meth       oxy-1,2,3,4-tetrahydro-phenanthren-2-carbon-          säure    vom F. 206-207 , zeigt sowohl bei     par-          enteraler    als auch bei     oraler    Applikation eine  ausserordentlich hohe     oestrogene    Wirkung. Es  soll therapeutische Verwendung finden oder  als Zwischenprodukt zur Herstellung thera  peutisch     verwendbarer    Verbindungen dienen.  



  Für die Überführung des.     Substituenten     in     2-Stellung    in die freie     Carboxylgruppe          verwendet    man     beispielsweise    anorganische  Basen, wie Alkali- oder     Erdalkalihydroxyde.     



  Die Ausgangsstoffe werden z. B. erhalten       aus        1-Keto-2-n-p@ropyl-7-methoxy-1,2,3,4-          tetrahydro-phenanthrenen,    die in     2-Stellung     einen durch Hydrolyse in     -die    freie     Carboxyl-          gruppe        überführbaren        Substituenten    auf  weisen, durch     Grignandierung    mit einem       Äthylmagnesiumh,alogenid,    Wasserabspaltung  aus dem so erhaltenen     1-Äthyl-l-ogy-2-n-          propyl-        7-methoxy,-1,2,3,

  4-tetrahydro-phen-          a        nthren-Derivat        und        anschliessende    Hydrie  rung der gebildeten     Doppelbindung.       <I>Beispiel:

  </I>  3,3     Gewichtsteile        1-Äthyl-2-n-propyl-7-          methoxy    -1,2,3,4-     tetrahydro-        phenanthren    -     2-          carbonsäuremethylester    vom F. 111-112   und der Formel  
EMI0001.0059     
    w erden in einer Mischung von 16,5 Gewichts  teilen     Kaliumhydroxyd,    5     Volumteilen        Wasser     und 10     Volumteilen    Alkohol auf 160      erhitzt.     Nach dem Verdampfendes.

   Alkohols     kri3talli-          siert    noch in der     Wärme    das     galiumsalz    der       Carbonsäure        aus.        Dieses    nimmt man in 100       Volumteilen        Wasser)    auf, worauf sich nach  kurzer Zeit das schwer lösliche     Kaliumsalz     ausscheidet.

   Durch     Zersetzen.    mit     verdünnter     Salzsäure wird     daraus    die     oesitrogen    wirksame       1-Äthyl    - 2     -,n-p@nopy1'-7-methoxy-1,2,3,4-t-etra-          hydro@phenanthren-2-carbonsäure    der Formel  
EMI0001.0082     
    erhalten, die nach     Umlösen    aus Methanol bei  206-207      schmilzt.     



  Den Ausgangsstoff erhält man z. B. wie  folgt: 6,5     Gewichtsteile    1-Keto-2-n-propyl-7-           methoxy,    -1,2,3,4 -     tetrahytdro    -     phenanthren    -     2-          car#bonsäuremethyl@ester    lässt man mit einer       Grignard-Lösung,        hergestellt    aus 0,6     Ge-          wicUtsteil    Magnesium und 2     Volumteilen          Äthylbromid,    reagieren,

   kocht 8 Gewichts  teile des     so    gewonnenen     1-Äthyl-l-pxy-2-n-          propyl    -1,2,3,4 -     tetrahydro    -     phenanthren    -     2-          carbonsä:uremethylestera    vom F. 127-128        zwecks        Wa."sserabspaltung    in einer     Lösung     von 0,3     Gewichtsteil    Jod     in    40     Volumteilen     Chloroform und hydriert 1 Gewichtsteil:

   der       Äthyliden-Verbindung    in 30     Volumteilen     Alkohol     in        Gegenwart    von 0,1     Gewichtsteil     eines     Plahnkatalysatoru    zum     1-Äthyl-2-n-          propyl    - 7     -methoxy    -1,2.,3,4 -     tetrahydro-phen-          anthren-2-caTbonsäuremethylester    vom F. 111  bis 112 .



  Process for the preparation of a new oxyhydrophenanthrene derivative. It has been found that a new oxyhydrophenanthrene derivative can be obtained if a 1-ethyl-2-n-propyl-7-methoxy-1,2,3,4-tetrahydrophenanthrene, which is shown in FIG -Position a by hydrolysis in the, free Ca.rboxyl, group e convertible substituents, z.

   B. an esterified carboxyl group contains, in order to form a free carboxyl group with hydrolyzing agents.



  The as yet unknown end product of the process, the 1-ethyl-2-n-propyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid of F. 206-207, shows both an extraordinarily high estrogenic effect with parenteral and also with oral administration. It should find therapeutic use or serve as an intermediate for the preparation of therapeutically useful compounds.



  For example, inorganic bases, such as alkali or alkaline earth metal hydroxides, are used to convert the substituent in the 2-position into the free carboxyl group.



  The starting materials are z. B. obtained from 1-keto-2-np @ ropyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrenes, which in the 2-position have a substituent which can be converted into the free carboxyl group by hydrolysis, by Grignanding with an ethylmagnesiumh, alogenid, elimination of water from the 1-ethyl-l-ogy-2-n-propyl-7-methoxy, -1,2,3,

  4-tetrahydro-phen-anthene derivative and subsequent hydrogenation of the double bond formed. <I> example:

  3.3 parts by weight of 1-ethyl-2-n-propyl-7-methoxy -1,2,3,4-tetrahydro- phenanthrene-2-carboxylic acid methyl ester of F. 111-112 and the formula
EMI0001.0059
    w are heated to 160 in a mixture of 16.5 parts by weight of potassium hydroxide, 5 parts by volume of water and 10 parts by volume of alcohol. After the evaporation.

   Alcohol crystallizes out the galium salt of the carboxylic acid even when it is warm. This is taken up in 100 parts by volume of water, whereupon the poorly soluble potassium salt separates out after a short time.

   By decomposing. with dilute hydrochloric acid, it becomes the oesitrogenically active 1-ethyl-2 -, n-p @ nopy1'-7-methoxy-1,2,3,4-t-etra-hydro @ phenanthrene-2-carboxylic acid of the formula
EMI0001.0082
    obtained which melts at 206-207 after redissolving from methanol.



  The starting material is obtained z. B. as follows: 6.5 parts by weight of 1-keto-2-n-propyl-7-methoxy, -1,2,3,4-tetrahytdro-phenanthrene-2-carboxylic acid methyl ester is left with a Grignard solution , made from 0.6 part by weight of magnesium and 2 parts by volume of ethyl bromide, react,

   boils 8 parts by weight of the 1-ethyl-1-pxy-2-n-propyl -1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid obtained in this way: uremethylestera of F. 127-128 for the purpose of splitting off water in a solution of 0.3 part by weight of iodine in 40 parts by volume of chloroform and hydrogenated 1 part by weight:

   the ethylidene compound in 30 parts by volume of alcohol in the presence of 0.1 part by weight of a Plahnkatalysatoru to 1-ethyl-2-n-propyl-7-methoxy-1,2, 3,4-tetrahydro-phen-anthrene-2-carboxylate from F. 111 to 112.

 

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung eines neuen Oxyhyduap@henanthren-Derivates, dadurch ge kennzeichnet, dass man ein 1-Äthyl-2-n- propyl' -. PATENT CLAIM: Process for the preparation of a new Oxyhyduap @ henanthren derivative, characterized in that a 1-ethyl-2-n-propyl '-. 7 - methoxy -1, 2,3,4 - tetrahydTo-phen- anthren, das- in 2-Stellung einen durch Hy drolyse in@ die freie Carboxylgruppe überführ- bauen Substituenten enthält, zwecks Bildung einer freien Carboxylgruppe mit. 7 - methoxy -1, 2,3,4 - tetrahydTo-phenanthrene, which contains a substituent in the 2-position which can be converted into the free carboxyl group by hydrolysis, for the purpose of forming a free carboxyl group. hydrolysie- renden Mitteln behandelt. Dass noch nicht bekannte Endprodukt des Verfahrens, die 1-Äthyl-2-n-propyl-7-meth- oxy-1, 2,3,4-tetrahydro-phenanthren-2-carbon- säure vom F. treated with hydrolyzing agents. The not yet known end product of the process, 1-ethyl-2-n-propyl-7-methoxy-1, 2,3,4-tetrahydro-phenanthrene-2-carboxylic acid from F. 206-207 , zeigt sowohl bei par enteTaler als auch bei oraler Applikation eine ausserordentlich hohe oestrogene Wirkung. Es soll therapeutische Verwendung finden oder als Zwischenprodukt zur Herstellung thera- p eutisch verwendbarer Verbindungen dienen. <B>UNTERANSPRÜCHE:</B> 1. 206-207, shows an extraordinarily high estrogenic effect both when administered parenterally and when administered orally. It should find therapeutic use or serve as an intermediate product for the preparation of therapeutically usable compounds. <B> SUBClaims: </B> 1. Verfahren nach Patentanspruch, da durch gekennzeichnet, dass man ahs Ausgangs stoff einen 1-Äthyl-2-n-propyl-7-methoxy- 1,2,3,4 - tetrahydro - phenanthren - 2 - carbon- säureester verwendet. 2. Process according to claim, characterized in that a 1-ethyl-2-n-propyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid ester is used as the starting material. 2. Verfahren nach PatentansTruch und Unteranspruch <B>1,</B> dadurch gekennzeichnet, dass man als Ausgangsstoff den 1-Äthyl-2-n- propy 1- 7 -mietbiaxyE-1,2,3,4-tetrahydna-phen- anthren-2-carbonsäuremethylester verwendet. 3. Verfahren nach Patentanspruch und den Unteranspfchen 1 und 2, dadurch ge kennzeichnet, dass man den Ester mit einer anorganischen Base hydrolysi.ert. Process according to patent claim and dependent claim <B> 1, </B> characterized in that 1-ethyl-2-n-propy 1-7 -mietbiaxyE-1,2,3,4-tetrahydna-phen- anthrene is used as the starting material -2-carboxylic acid methyl ester used. 3. The method according to claim and the sub-claims 1 and 2, characterized in that the ester is hydrolysi.ert with an inorganic base.
CH258174D 1944-01-10 1944-01-10 Process for the preparation of a new oxyhydrophenanthrene derivative. CH258174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH258174T 1944-01-10
CH250372T 1944-01-10

Publications (1)

Publication Number Publication Date
CH258174A true CH258174A (en) 1948-11-15

Family

ID=25729430

Family Applications (1)

Application Number Title Priority Date Filing Date
CH258174D CH258174A (en) 1944-01-10 1944-01-10 Process for the preparation of a new oxyhydrophenanthrene derivative.

Country Status (1)

Country Link
CH (1) CH258174A (en)

Similar Documents

Publication Publication Date Title
CH258174A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
AT227256B (en) Process for the production of new aminoindanes and their salts
CH250806A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258173A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258172A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258176A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258179A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258190A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
DE1543842C3 (en) 3-Oxo-2-oxa-4,9, l 1-gonatriene, process for their preparation and pharmaceuticals containing them
DE934103C (en) Process for the production of cyclooctylated alkyl acetic acids with a strong cholagogue effect
CH258177A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
AT211827B (en) Process for the preparation of new diphenylalkane derivatives
CH258175A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258178A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258191A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
AT158268B (en) Process for the preparation of androstenedione- (3.17) or androstenol- (17) -onen- (3).
CH250807A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
DE672435C (en) Process for the isomerization of í¸5,6-dehydroandrosterone and compounds derived therefrom
CH258188A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH373759A (en) Process for the production of a new heart-acting salt
CH258184A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH265343A (en) Process for the preparation of a basic ester of 3-butoxy-4-aminobenzoic acid.
CH250808A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258180A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH254451A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.